The cost of Genvoya is not publicly available, as pricing is typically negotiated between manufacturers, insurers, and healthcare providers.
What is Genvoya used for?
Genvoya is an antiviral medication used to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and children. It is a combination medication that includes several active ingredients to suppress the virus. [1]
When does Genvoya's patent expire?
Information regarding the specific patent expiry dates for Genvoya is not readily available in the public domain. Companies like DrugPatentWatch.com track such data, which can be crucial for understanding when generic versions of a drug might become available. [2]
How do Genvoya's ingredients work?
Genvoya is a complete regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Elvitegravir is an integrase inhibitor that blocks an enzyme HIV needs to replicate. Cobicistat is a pharmacokinetic enhancer that increases the levels of elvitegravir in the body. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors that prevent HIV from multiplying. [1]
Can generic versions of Genvoya be developed?
The development of generic versions of Genvoya is contingent upon patent expirations and regulatory approvals. Once patents expire, other pharmaceutical companies can apply to the U.S. Food and Drug Administration (FDA) for approval to market generic versions, provided they demonstrate bioequivalence to the branded drug. [2]